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A B S T R A C T
Background. During the past 15 years, closure of a secundum atrial septal defect (ASD) has moved from a surgical
to a percutaneous transcatheter approach. Few long-term studies of the efficacy and safety of closure of an ASD by
an Amplatzer septal occluder (ASO) exist.
Methods. To examine the long-term results of secundum ASD closure using the ASO, data on 94 patients who
underwent secundum ASD closure with the ASO between 1998 and 2002 were available and reviewed. Data
regarding residual shunt, chest pain, palpitations, arrhythmias, headaches, transient ischemic attacks, cerebrovascu-
lar accidents, and mortality were collected.
Results. Seven (7.4%) subjects had residual shunts immediately following ASO placement. During follow-up, 4
residual shunts closed for a complete closure rate of 97%. Eighteen (19%) patients reported chest pain during the
follow-up period. Twenty-three patients (24%) reported palpitations during the follow up period, 7 were docu-
mented arrhythmias, including supraventricular tachycardia, atrial fibrillation, and premature ventricular beats.
Migraine headaches were new-onset in 4 patients. Migraine cessation occurred in 2 patients after secundum ASD
closure. One child died from a cerebral vascular event 18 months following device placement. Only 1 patient
developed mild aortic insufficiency.
Conclusion. These data indicate that for up to 120 months of patient follow-up, the ASO continues to be a safe
device. Residual shunts and arrhythmias have low incidence post-ASO placement. Given the mortality in one
high-risk patient, further investigation into anti-platelet therapy after device placement is warranted.
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Introduction
During the past 15 years, closure of secundumatrial septal defects (ASD) has moved from a
surgical approach in the operating room to a per-
cutaneous transcatheter approach in the cardiac
catheterization laboratory.1 Reports of transcath-
eter secundum ASD closure studies have shown
improvement in cardiac dimensions and function,
as well as right ventricular systolic pressure and
pulmonary artery hypertension.2–4 In contrast to
surgical closure, the transcatheter approach avoids
cardiopulmonary bypass, results in shorter hospi-
talization, reduces need for blood products, lessens
patient discomfort, produces similar outcomes,
and decreases costs.5–8 One such device used for
transcatheter closure, the Amplatzer septal
occluder (ASO), was initially used in humans in
1995.9 Short- and intermediate-term studies have
shown the device to be safe and effective.10,11
Given that few long-term studies of the ASO
exist,12 and complications after device placement
continue to be reported,13–15 this report summa-
rizes long-term secundum ASD closure outcomes
using the ASO.
Methods
From our pediatric catheterization laboratory
device database, 159 patients who had undergone
secundum ASD closure with the ASO between
1998 and 2002 were identified. Ninety-four
patients were pediatric (18 years of age) and 65
were adults (19 years) at the time of device place-
ment. The study was approved by the institutional
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review board. If the patient did not receive
follow-up care at our institution, a HIPAA (Health
Insurance Portability and Accountability Act)-
compliant release of information was sought for
outside records to be reviewed. Of the 159 patients,
7 patients chose not to be included in the study, 29
patients were lost to follow up, and 29 patients did
not respond to requests. The overall response rate
was 59%. The study population then comprised of
94 patients (52 pediatric, 42 adult); each subject’s
medical record was reviewed from presentation at
our institution through March of 2008. The fol-
lowing outcomes were collected: residual shunt,
chest pain, palpitations, arrhythmias, headaches,
transient ischemic attacks (TIA), cerebrovascular
accidents (CVA), and mortality. Mean age at
implantation for pediatric patients was 7.5  4.6
years, and for adults was 49.9  15.4 years.
All patients had a physical examination, ECG,
and echocardiogram prior to device placement.
The Amplatzer septal occluder (AGA Medical,
Golden Valley, MN) was used exclusively in the
group studied. Technical delivery of the device to
the atrial septum has been previously described.9
All defects were measured using the balloon
stretched diameter technique. Intra-procedural
heparin and antibiotics were given to all patients.
After device placement, patients received 6
months of aspirin therapy. All had repeat physical
examinations, ECG, and echocardiograms 6
months after device placement. Further follow-up
and surveillance testing were determined by the
patient’s primary cardiologist.
Data are expressed in mean  standard devia-
tion or median with range as appropriate.
Results
Median follow up was 73 months (range 63–120).
There were 7487 patient-months of follow up.
Mean secundum ASD size by balloon stretched
diameter was 18.0  5.7 mm. Mean size of ASO
used was 19  6 mm, yielding a mean device to
stretched defect ratio of 108%. In the pedia-
tric group, 16 (31%) received devices with dia-
meters greater than 1 mm/kg body weight, and
one child had a device diameter greater than
2 mm/kg.
A total of 7 (7.4%) residual shunts were present
immediately following ASO placement. However,
in the follow-up period 4 residual shunts closed
for a complete closure rate of 97% (Table 1). The
remaining residual shunts were not hemodynami-
cally significant on echocardiography.
Eighteen (19%) patients reported chest pain
during the follow-up period (Table 2). No com-
plaints of chest pain were reported in the first
month. All patients with chest pain received
workup; only 2 patients were identified with
cardiac sources of the chest pain. One pediatric
patient had supraventricular tachycardia (SVT)
diagnosed by ECG. This occurred 25 months
post-device placement. One adult patient had
hemorrhagic pericarditis 9 months after device
placement. No erosion of the device was noted by
physical examination, chest x-ray, or echocardio-
gram. The patient underwent uncomplicated peri-
cardial window and drainage with the device left in
place and recovered completely.
Table 1. Prevalence of residual shunts after ASO
placement
<1 month 1–12 months 1–5 years >5 years
Pediatric 2 (4%) 2 (4%) 1 (2%) 1 (2%)
Adult 5 (12%) 4 (10%) 2 (5%) 2 (5%)
Total 7 (7%) 6 (6%) 3 (3%) 3 (3%)
Time period after device placement is listed with the corresponding number of
residual shunts.
Table 2. Incidence of chest pain, palpitations, and arrhythmias after placement of Amplatzer septal occluder. Each column
represents the incidence of the symptom occurring during the time period after device placement.
Outcome <1 month 1–12 months 1–5 years >5 years
Chest Pain Pediatric 0 (0%) 2 (4%) 4 (8%) 5 (10%)
Adult 0 (0%) 3 (7%) 3 (7%) 3 (7%)
Total 0 (0%) 5 (5%) 7 (7%) 8 (15%)
Palpitation Pediatric 0 (0%) 1 (2%) 5 (10%) 2 (4%)
Adult 5 (12%) 7 (17%) 3 (7%) 0 (0%)
Total 5 (5%) 8 (15%) 8 (15%) 2 (2%)
Arrhythmia Pediatric 0 (0%) 0 (0%) 1 (SVT) (2%) 1 (1° AVB) (2%)
Adult 2 (Afib, SVT) (5%) 2 (Afib, PVC) (5%) 1 (Afib) (2%) 0 (0%)
Total 2 (2%) 2 (2%) 2 (2%) 1 (1%)
Afib, atrial fibrillation, PVC, premature ventricular complexes, SVT, supraventricular tachycardia, 1° AVB, first degree atrioventricular block.
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Prior to device placement, 14 patients (15%)
had documented arrhythmias. This included three
pediatric patients with SVT, none of whom had
recurrence of SVT in follow up. One adult had
SVT, which did not recur after device placement.
Ten adult patients, all of whom were over 40 years
of age at the time of device placement, had prior
atrial fibrillation. Eight of these 10 adults con-
tinued to have atrial fibrillation in the follow up
period.
Twenty-three patients (24%) reported palpita-
tions during the follow up period (Table 2).
However, only 7 (7%) patients had documented
new-onset arrhythmias (Table 2). In the pediatric
subset, one child had SVT, as noted in the section
regarding chest pain above. This child had a pre-
senting symptom of chest pain, but did not report
palpitations. She did not have evidence of pre-
excitation. The child had two more episodes of
SVT over the next two months; she was started on
digoxin with no more episodes in the following
5-year period. One child was noted to have first-
degree atrioventricular block found incidentally
on a surveillance ECG. Three (7%) adults devel-
oped new-onset atrial fibrillation. Another adult
had a first-time, single episode of SVT 2 weeks
following device placement. Another had frequent
premature ventricular complexes on work-up;
these had not been documented prior to device
placement.
Migraine headaches were new-onset in 4 (4%)
patients during the follow up period. Conversely,
2 (2%) patients who had suffered from migraine
headaches prior to secundum ASD closure with
the ASO did not have a migraine headache during
the follow up period. Though three adults had
TIAs or CVAs prior to ASO placement, no adults
had further neurologic events. One child had a
fatal CVA 18 months following device placement.
Review of the echocardiographic data showed
that 77 patients (82%) had mild dilation of the
right sided chambers at time of device implanta-
tion. Additionally, nine patients (10%) had mod-
erate right sided chamber dilation, while eight
patients (8%) had no chamber enlargement.
During the follow-up period, 37 of the 44 pediat-
ric patients (84%) with mild right-sided chamber
dilation had resolution to normal chamber dimen-
sions. Nineteen of the 33 adult patients (58%) had
resolution of mild right sided dilation. However,
three adults with mild dilation had worsening to
moderate dilation during the follow up period. All
three of these patients were over the age of 60 at
time of device implantation. Lack of a change in
right-sided dilation after device implantation was
less common in the pediatric subset [9 out of 52
(17%)], compared to the adult subset [13 out of 42
(31%)].
No pediatric patient developed aortic insuffi-
ciency after placement of the ASO. One (2%)
adult patient developed mild aortic insufficiency
evident only by echocardiography in the follow
up period. In addition, no perforations occurred
during the device implantation. One child did
have an atrial mass on follow-up echocardiogram
(see description below), and no other patients had
thrombi or masses identified during the follow up
period.
Discussion
Our study showed that use of the ASO resulted in
very high incidence (97%) of complete closure.
Among rare cases of residual shunt, the majority
closed spontaneously. Though recent reports have
suggested that transthoracic echocardiography
was sufficient to determine ASO size,16 all devices
in our study were chosen based on defect stretched
diameter. This method likely contributed to our
low rate of residual shunts.
Chest pain was a common complaint through-
out the follow-up period. Although the complaint
was common, a cardiac etiology was rare. Interest-
ingly, no patient complained of chest pain during
the first month after ASO placement. This obser-
vation may be related to the counseling that
patients received prior to device placement, mini-
mizing potential concerns a patient may have in
the immediate post-placement period. This may
have led to under-reporting of symptoms. One
patient had chest pain due to a tachyarrhythmia, a
known cause of chest discomfort.
Similarly, palpitations were reported quite
infrequently in pediatric patients. Adults, con-
versely, complained more frequently of palpita-
tions earlier in the post-placement period. Again,
pre-device counseling may have led to under-
reporting. However, only 25% of children with
complaints of palpitations had a documented
arrhythmia.
Several patients had documented arrhythmias
prior to device implantation. Interestingly, none
of the pediatric patients had recurrence of
arrhythmia after device placement. Conversely,
nearly 80% of the adult patients had recurrence
of their atrial fibrillation after device placement.
This appears to be very similar to what has been
described in the adult surgical literature,17,18 in
Knepp et al.34
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which data suggest that patients who are older at
the time of intervention are more likely to have
recurrence of atrial arrhythmias. All of our adult
patients who had recurrence of their atrial
arrhythmias were older than 50 at the time of
implantation, except one patient who was 41
years old. The 3 of 11 adult patients that did not
have recurrences were 47, 63, and 79 years of
age.
In addition, 10% of adults developed a new
arrhythmia post-ASO placement. All of these
patients were older than 50 years at the time of
device placement. This observation, however, may
be independent of the ASO. The expected course
of a dilated atrium is to develop arrhythmias;19 one
could then postulate that the development of atrial
fibrillation in the adult sub-group was indepen-
dent of the device being placed.
The pediatric patient with SVT after device
implantation did have a mildly dilated right atrium
that did not improve after device placement. The
child had no residual shunting on follow up
echocardiograms and the device was well seated.
The SVT began about one month following the
placement of the device and, therefore, was con-
cluded to be related to the device.
The rates of preoperative atrial arrhythmias in
our series are comparable to published surgical
series. In the series by Murphy,20 19 (15%) of their
patients had atrial flutter or fibrillation prior
to surgical ASD closure. Thirteen of those 19
patients (68%) continued to have atrial arrhyth-
mias post surgical closure, comparable to our rate
of 57% after ASO placement. In the same surgical
series, 23% developed an arrhythmia during the
follow-up period. This is higher than our 7% rate,
though the follow up in the surgical series was
between 27 and 32 years. As would be expected,
patients who were older at the time of ASD had
more arrhythmic events.
The development of migraine headaches in our
study group was small, as was the resolution of
migraine headaches following device placement.
Many studies have looked at the association
between patent foramen ovale (PFO) and
migraine headaches.21,22 Prospective trials have
also examined PFO closure with an implantable
device as a treatment option.23 In our study, we
only evaluated patients with device closure of
secundum ASD. Although there is an overlap
between adults with PFO and secundum ASD, it
is not possible to make a generalization about the
relationship between migraines and ASO closure
of secundum ASD.
The case of hemorrhagic pericarditis has many
confounding factors. Though it could be assumed
that this was directly related to the device implan-
tation, no perforation was noted during the case
or in any of the follow up echocardiograms. The
follow up echocardiograms had shown the device
to be well seated. At the time of surgery, no device
erosion was identified by the surgeon. The patient
had been using injectible illicit substances and was
intoxicated at the time of admission. In addition,
culture of the contents of the pericardium grew
coagulase-negative staphylococcus.
The lone mortality in our follow up occurred in
a child who had a fatal cerebrovascular accident 18
months following device placement. At the time
of device placement, he was 25 months old and
weighed 9 kg. He had a large ASD, trisomy 21,
poor growth, and significant respiratory illnesses
requiring multiple hospitalizations. The child had
been felt to be high risk for surgical closure.
Therefore, he underwent percutaneous closure
with an ASO under general anesthesia with transe-
sophageal echocardiographic guidance. The
balloon stretched diameter was 18.6 mm. A
20-mm ASO was placed, but resulted in immedi-
ate complete heart block; the device was removed
and the child resumed sinus rhythm. An 18 mm
ASO was then placed with no residual shunt
or arrhythmia. Intraoperative transesophageal
echocardiogram revealed the left atrial disc abut-
ting the anterior leaflet of the mitral valve. The
mitral valve was not distorted, and no mitral steno-
sis and trace mitral regurgitation were seen. The
child was maintained on aspirin for 6 months post
procedure and had normal follow up echocardio-
grams. Eighteen months after device placement,
he developed fever, lethargy, and no movement on
the right side. He quickly became obtunded and
was sent to the local emergency department. A CT
scan of the head demonstrated occlusion of the
left internal carotid artery and a left frontal lobe
infarct. Echocardiogram found normal biventricu-
lar function, no residual shunt, and a 1 cm ¥
0.5 cm mass in the left atrium attached to the atrial
septum and extending to the posterior leaflet of
the mitral valve. No significant mitral stenosis or
regurgitation was seen. The patient rapidly dete-
riorated despite neurosurgical intervention, and
support was withdrawn. Autopsy demonstrated a
left atrial thrombus adherent to the inferior edge
of the device overlying the mitral valve leaflet
(Figure 1). Other than this region, the device
appears to be endothelialized. Thrombus was
partially organized with abundant neutrophil
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infiltrate, but no infection was identified. It is not
known if the child had a hypercoagulable state.
Verification of device endothelialization with
microscopy was not performed. Although not
studied prospectively, the use of aspirin therapy for
6 months has been our protocol for device place-
ment and is based on the amount of time that a
majority of ASOs become endothelialized.24,25
The limitations of this study include those
inherent to retrospective reviews. The overall
response rate was only about 60%, which raises
the possibility that some adverse events may not
have been reported. Due to institutional regula-
tions, further investigation into follow up records
is limited. However, given that our institution was
the first and only center placing ASOs in our
region during the first several years of follow up,
it is very likely that any complication would
have been brought back to our institution for
evaluation.
Conclusion
These data indicate that for up to 120 months of
patient follow-up, the ASO is a safe device for
secundum atrial septal defect closure in both pedi-
atric and adult patients. Residual shunts and
arrhythmias have low incidence post-ASO place-
ment. The ASO continues to compare favorably
to surgical closure. Given the mortality in one
high-risk patient, we feel further investigation into
anti-platelet therapy after device placement is
warranted.
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